rdwvsm4s

Property	Value
?:abstract	BACKGROUND: The impact of corticosteroid therapy on outcomes of patients with coronavirus disease 2019 (COVID-19) is highly controversial. We aimed to compare the risk of death between COVID-19-related ARDS patients with corticosteroid treatment and those without. METHODS: In this single-center retrospective observational study, patients with ARDS caused by COVID-19 between January 20, 2020, and February 24, 2020, were enrolled. The primary outcome was 60-day in-hospital death. The exposure was prescribed systemic corticosteroids or not. Time-dependent Cox regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for 60-day in-hospital mortality. RESULTS: A total of 382 patients [60.7 ± 14.1 years old (mean ± SD), 61.3% males] were analyzed. The median of sequential organ failure assessment (SOFA) score was 2.0 (IQR 2.0–3.0). Of these cases, 94 (24.6%) patients had invasive mechanical ventilation. The number of patients received systemic corticosteroids was 226 (59.2%), and 156 (40.8%) received standard treatment. The maximum dose of corticosteroids was 80.0 (IQR 40.0–80.0) mg equivalent methylprednisolone per day, and duration of corticosteroid treatment was 7.0 (4.0–12.0) days in total. In Cox regression analysis using corticosteroid treatment as a time-varying variable, corticosteroid treatment was associated with a significant reduction in risk of in-hospital death within 60 days after adjusting for age, sex, SOFA score at hospital admission, propensity score of corticosteroid treatment, comorbidities, antiviral treatment, and respiratory supports (HR 0.42; 95% CI 0.21, 0.85; p = 0.0160). Corticosteroids were not associated with delayed viral RNA clearance in our cohort. CONCLUSION: In this clinical practice setting, low-dose corticosteroid treatment was associated with reduced risk of in-hospital death within 60 days in COVID-19 patients who developed ARDS.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/rdwvsm4s_hasAnnotation_C0035736> <https://research.tib.eu/covid-19/entity/rdwvsm4s_hasAnnotation_C1825598>
?:creator	<https://research.tib.eu/covid-19/entity/Wu%2C_Chaomin%3B_Hou%2C_Dongni%3B_Du%2C_Chunling%3B_Cai%2C_Yanping%3B_Zheng%2C_Junhua%3B_Xu%2C_Jie%3B_Chen%2C_Xiaoyan%3B_Chen%2C_Cuicui%3B_Hu%2C_Xianglin%3B_Zhang%2C_Yuye%3B_Song%2C_Juan%3B_Wang%2C_Lu%3B_Chao%2C_Yen-cheng%3B_Feng%2C_Yun%3B_Xiong%2C_Weining%3B_Chen%2C_Dechang%3B_Zhong%2C_Ming%3B_Hu%2C_Jie%3B_Jiang%2C_Jinjun%3B_Bai%2C_Chunxue%3B_Zhou%2C_Xin%3B_Xu%2C_Jinfu%3B_Song%2C_Yuanlin%3B_Gong%2C_Fengyun>
?:doi	<https://research.tib.eu/covid-19/entity/10.1186/s13054-020-03340-4>
?:doi	10.1186/s13054-020-03340-4
?:journal	Crit_Care
?:license	cc-by
?:pdf_json_files	document_parses/pdf_json/61071898ac5095d8ee60e72bb4e9cb92fbe99eb2.json
?:pmc_json_files	document_parses/pmc_json/PMC7655069.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7655069>
?:pmid	<https://research.tib.eu/covid-19/entity/33172477.0>
?:pmid	33172477.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/rdwvsm4s_HAS_C5203670_CAUSES_C0035222>
?:sha_id	<https://research.tib.eu/covid-19/entity/61071898ac5095d8ee60e72bb4e9cb92fbe99eb2>
?:source	Medline; PMC
?:title	Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-11-10

Property

Value

?:abstract

BACKGROUND: The impact of corticosteroid therapy on outcomes of patients with coronavirus disease 2019 (COVID-19) is highly controversial. We aimed to compare the risk of death between COVID-19-related ARDS patients with corticosteroid treatment and those without. METHODS: In this single-center retrospective observational study, patients with ARDS caused by COVID-19 between January 20, 2020, and February 24, 2020, were enrolled. The primary outcome was 60-day in-hospital death. The exposure was prescribed systemic corticosteroids or not. Time-dependent Cox regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for 60-day in-hospital mortality. RESULTS: A total of 382 patients [60.7 ± 14.1 years old (mean ± SD), 61.3% males] were analyzed. The median of sequential organ failure assessment (SOFA) score was 2.0 (IQR 2.0–3.0). Of these cases, 94 (24.6%) patients had invasive mechanical ventilation. The number of patients received systemic corticosteroids was 226 (59.2%), and 156 (40.8%) received standard treatment. The maximum dose of corticosteroids was 80.0 (IQR 40.0–80.0) mg equivalent methylprednisolone per day, and duration of corticosteroid treatment was 7.0 (4.0–12.0) days in total. In Cox regression analysis using corticosteroid treatment as a time-varying variable, corticosteroid treatment was associated with a significant reduction in risk of in-hospital death within 60 days after adjusting for age, sex, SOFA score at hospital admission, propensity score of corticosteroid treatment, comorbidities, antiviral treatment, and respiratory supports (HR 0.42; 95% CI 0.21, 0.85; p = 0.0160). Corticosteroids were not associated with delayed viral RNA clearance in our cohort. CONCLUSION: In this clinical practice setting, low-dose corticosteroid treatment was associated with reduced risk of in-hospital death within 60 days in COVID-19 patients who developed ARDS.

is ?:annotates of